Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Inventory (2023 - 2025)

Historic Inventory for Verrica Pharmaceuticals (VRCA) over the last 3 years, with Q3 2025 value amounting to $2.3 million.

  • Verrica Pharmaceuticals' Inventory fell 1083.59% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1083.59%. This contributed to the annual value of $2.5 million for FY2024, which is 14099.8% up from last year.
  • Latest data reveals that Verrica Pharmaceuticals reported Inventory of $2.3 million as of Q3 2025, which was down 1083.59% from $2.5 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Inventory high stood at $2.7 million for Q2 2024, and its period low was $279000.0 during Q3 2023.
  • For the 3-year period, Verrica Pharmaceuticals' Inventory averaged around $2.1 million, with its median value being $2.5 million (2024).
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Inventory skyrocketed by 82616.49% in 2024, and later plummeted by 1083.59% in 2025.
  • Quarter analysis of 3 years shows Verrica Pharmaceuticals' Inventory stood at $1.0 million in 2023, then soared by 141.0% to $2.5 million in 2024, then dropped by 6.46% to $2.3 million in 2025.
  • Its Inventory stands at $2.3 million for Q3 2025, versus $2.5 million for Q2 2025 and $2.5 million for Q1 2025.